Open Nav

Please submit your session questions in advance at

Armando Anido


Zynerba Pharmaceuticals

Armando Anido has served as our Chairman and Chief Executive Officer(CEO) since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly trade companies: NuPathe (NASDAQ: PATH), which was acquired by Teva Pharmaceuticals in February 2014, where he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine; and Auxilium Pharmaceuticals (NASDAQ: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. He is currently a member of the Board of Directors of PA Bio, and he was a member of the Board of Directors of Adolor until it was sold to Cubist in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.

This speaker's sessions: